An open ended equity scheme investing in pharma sector

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

June 5, 2004

Sailesh Raj Bhan

S&P BSE Healthcare TRI

Monthly Average :	₹ 4,527.00 Cr
Month End :	₹ 4,421.86 Cr

Growth Plan	₹275.5014
IDCW Plan	₹76.5016
Bonus Option	₹275.5014
Direct - Growth Plan	₹300.225
Direct - IDCW Plan	₹102.5232
Direct - Bonus Option	₹300.225

Entry Load:	Nil
Exit Load:	1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units. Nil, thereafter.

Standard Deviation	6.12
Beta	0.91
Sharpe Ratio	0.20
Note: The above measures have been calculated using monthly rolling returns for 36 months period with 6.5% risk free return (FBIL Overnight MIBOR as on 31/01/2023).

Portfolio Turnover

0.20

Regular/Other than Direct	1.99
Direct	1.17

N.A: Since TRI data is not available prior to 23/08/2004 for S&P BSE Healthcare , performance for such period is not provided
Past performance may or may not be sustained in future. It is assumed that a SIP of ₹ 10,000 each executed on 10th of every month including the first installment in the Growth option of the Fund. Returns on SIP and Benchmark are annualized and cumulative investment return for cash flows resulting out of uniform and regular monthly subscriptions have been worked out on excel spreadsheet function known as XIRR. Load has not been taken into consideration.
B: Benchmark, AB: Additional Benchmark, TRI: Total Return Index
TRI - Total Returns Index reflects the returns on the index arising from (a) constituent stock price movements and (b) dividend receipts from constituent index stocks, thereby showing a true picture of returns.
For scheme performance please click here. For Fund manager wise scheme performance click here.

Past performance may or may not be sustained in future. Pursuant to IDCW payment, NAV falls to the extent of payout & statutory levy (if applicable). Face Value-₹ 10.